GZMM
GZMM (granzyme M, also known as MET1 and LMET1) is a neutral serine protease stored in the cytoplasmic granules of natural killer cells and activated lymphocytes. It cleaves substrates after methionine, leucine and norleucine, and promotes caspase activation and apoptosis of target cells. Browse Assay Genie's current range of GZMM research reagents below, or read on for the biology behind the target.
GZMM is a serine protease that cleaves peptide substrates after methionine, leucine and norleucine. Its physiological substrates include ezrin (EZR), alpha-tubulins and the apoptosis inhibitor BIRC5 (survivin). By acting on these targets, granzyme M promotes caspase activation and subsequent apoptosis of target cells, which places it among the effector molecules of lymphocyte-mediated cell killing.
Human natural killer (NK) cells and activated lymphocytes express and store a distinct subset of neutral serine proteases, together with proteoglycans and other immune effector molecules, in large cytoplasmic granules. These proteases are collectively termed granzymes. Four distinct gene products are recognised in humans: granzyme A, granzyme B, granzyme H and granzyme M, the protein encoded by the GZMM gene. UniProt lists the protein as secreted and located in cytoplasmic granules, and places it in the peptidase S1 family, granzyme subfamily. Two transcript variants encoding different isoforms have been reported.
HGNC classifies the gene in the group of granule associated serine proteases of immune defence. Its previous name was granzyme M (lymphocyte met-ase 1), and the aliases MET1 and LMET1 reflect its preference for cleavage after methionine. A rat ortholog, Gzmm, is recorded for the gene.
Granzyme M is stored in granules of NK cells and activated lymphocytes, making it a relevant effector protease in studies of lymphocyte-mediated killing.
GZMM promotes caspase activation and apoptosis of target cells, and cleaves the apoptosis inhibitor survivin (BIRC5).
Granzyme M cleaves after methionine, leucine and norleucine, a distinct preference among the granzymes that suits substrate and cleavage studies.
Ezrin and alpha-tubulins are physiological substrates of granzyme M, linking the protease to cytoskeletal targets in cell death.
GZMM is a serine protease that cleaves peptide substrates after methionine, leucine and norleucine. Its physiological substrates include EZR, alpha-tubulins and BIRC5/survivin. It promotes caspase activation and subsequent apoptosis of target cells. Check the datasheet of any product for its validated reactivity.
Granzyme M is also known as MET1 and LMET1, and its previous HGNC name was granzyme M (lymphocyte met-ase 1). The gene produces two transcript variants that encode different isoforms, according to the NCBI Gene summary.
GZMM is one of four human granzymes, alongside granzyme A, granzyme B and granzyme H. All are neutral serine proteases stored in cytoplasmic granules of NK cells and activated lymphocytes. A rat ortholog, Gzmm, is recorded; no mouse ortholog is listed in the data.
Other granzymes, apoptosis regulators and substrates connected to lymphocyte-mediated cytotoxicity.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P51124; product specifications from Assay Genie datasheets.